Drugmakers, insurers, hospitals, pharmacies, medical devices, clinical updates, and healthcare business leaders.
Lilly’s planned purchase of 4E Therapeutics would broaden its neuroscience and anti-cancer research footprint, pairing the expansion with an incremental clinical update for Jaypirca, its targeted treatment for certain leukemias.
THE APEX TIMES
THE APEX TIMES
Moderna’s stock jumped about 9% in the afternoon session after traders moved ahead of a pivotal FDA advisory committee meeting tied to the company’s mRNA seasonal flu vaccine program.
THE APEX TIMES
Moderna shares extended a sharp 2026 rally, reviving investor questions about whether mRNA leadership is translating into relative strength versus older vaccine players such as Pfizer and rival developer Novavax.
THE APEX TIMES
The deal gives Eli Lilly a fresh portfolio of painkiller candidates developed by Austin-based 4E Therapeutics, as the drugmaker continues to chase safer alternatives to opioids.
THE APEX TIMES
Moderna’s shares jumped after a Yahoo Finance report said newly posted FDA materials appeared to point toward approval for the company’s mRNA-based influenza vaccine.
THE APEX TIMES
A fresh round of market chatter highlighted SpaceX’s sharp run-up, alongside other widely tracked names such as Western Digital and Moderna, underscoring how investors are rotating across sectors rather than following a single theme.
THE APEX TIMES
A market note citing one Wall Street analyst points to additional upside for CVS Health, though it offers few new operational details beyond the call itself.
THE APEX TIMES
In remarks reported by Yahoo Finance, Pfizer’s chief executive suggested the company could return to high-single-digit growth, a sign investors may be underestimating how quickly the business can stabilize.
THE APEX TIMES
A fresh market commentary points to Eli Lilly’s strong momentum, while warning that the stock’s price may already reflect a lot of good news, leaving less room for error.
